- Samsung Biologics has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland from GSK, marking its first manufacturing presence in the United States.
- The site adds 60,000 liters of capacity, bringing the company’s total global manufacturing capacity to 845,000 liters.
Samsung Biologics has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland from GSK, establishing its first manufacturing presence in the United States and expanding its global CDMO network.
The Rockville site includes two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity. The facility supports both clinical and commercial biologics production across multiple manufacturing scales. Following the acquisition, Samsung Biologics’ total global manufacturing capacity has increased to 845,000 liters.
Under the terms of the agreement, Samsung Biologics will continue supplying products previously manufactured at the site to GSK. The company stated that the facility will also transition to support additional contract manufacturing activities as part of its CDMO operations.
Samsung Biologics plans to invest further in the site to expand capacity and upgrade technologies. The company said these efforts are intended to support a geographically diversified manufacturing network and contribute to global supply chain resilience, while improving access to medicines.
“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family.”
John Rim, President and CEO of Samsung Biologics
